Effects of oral crystalline cyanocobalamin 1000 μg/d in the treatment of pernicious anemia: An open-label, prospective study in Ten Patients
- PMID: 24672108
- PMCID: PMC3964566
- DOI: 10.1016/j.curtheres.2005.02.001
Effects of oral crystalline cyanocobalamin 1000 μg/d in the treatment of pernicious anemia: An open-label, prospective study in Ten Patients
Abstract
Background: Standard treatment of cobalamin (vitamin B12) deficiency involvesregular (1000 μg/mo) IM cyanocobalamin administration. It has been suggested that high-dose (>2000 μg/d) oral cyanocobalamin may be effective in patients with pernicious anemia.
Objective: The aim of this study was to assess the efficacy and tolerability of oral crystalline cyanocobalamin 1000 μg/d in patients with cobalamin deficiency related to established pernicious anemia.
Methods: This open-label, prospective study was conducted at StrasbourgUniversity Hospital, Strasbourg, France. Patients aged ≥18 years with well-documented cobalamin deficiency related to pernicious anemia were enrolled. Patients received crystalline cyanocobalamin 1000 μg QD PO (capsule) for at least 3 months. Serum cobalamin, folate, iron, and homocysteine concentrations were measured, and a complete blood count was obtained, before (month 0; baseline) and after treatment.
Results: Ten patients (7 women, 3 men; mean [SD] age, 72.1 [15.5] years) entered the study. After 3 months of treatment, serum cobalamin concentration increased in all 9 patients in whom it was measured (mean [SD] increase, 117.4 [30.8] pg/mL; P < 0.001 vs baseline). Serum cobalamin concentrations were normalized (>200 pg/mL) in 6 patients. The serum cobalamin concentration was unavailable in 1 patient because of technical problems. Eight patients had increased hemoglobin concentrations (mean [SD] increase, 2.5 [2.4] g/dL; P < 0.01 vs baseline). All 10 patients had decreased mean erythrocyte corpuscular volumes (mean [SD] decrease, 10.4 [6.2] fL; P < 0.003 vs baseline). Four patients received concomitant blood transfusions or folate and iron supplementation. Three patients experienced clinical improvement in paresthesia, reflex abolition, or combined medullary sclerosis (each, 1 patient).
Conclusion: The results of this small study in patients with cobalamin deficiencyrelated to pernicious anemia suggest that oral crystalline cyanocobalamin 1000 μg/d may be an effective treatment.
Keywords: cobalamin deficiency; oral cyanocobalamin treatment; pernicious anemia.
Similar articles
-
Efficacy of short-term oral cobalamin therapy for the treatment of cobalamin deficiencies related to food-cobalamin malabsorption: a study of 30 patients.Clin Lab Haematol. 2003 Jun;25(3):161-6. doi: 10.1046/j.1365-2257.2003.00515.x. Clin Lab Haematol. 2003. PMID: 12755792 Clinical Trial.
-
Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study.Clin Ther. 2003 Dec;25(12):3124-34. doi: 10.1016/s0149-2918(03)90096-8. Clin Ther. 2003. PMID: 14749150 Clinical Trial.
-
A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations.J Am Geriatr Soc. 2002 Jan;50(1):146-51. doi: 10.1046/j.1532-5415.2002.50020.x. J Am Geriatr Soc. 2002. PMID: 12028259 Clinical Trial.
-
Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia.Front Med (Lausanne). 2016 Aug 23;3:38. doi: 10.3389/fmed.2016.00038. eCollection 2016. Front Med (Lausanne). 2016. PMID: 27602354 Free PMC article. Review.
-
Treatment of vitamin b(12)-deficiency anemia: oral versus parenteral therapy.Ann Pharmacother. 2002 Jul-Aug;36(7-8):1268-72. doi: 10.1345/aph.1A122. Ann Pharmacother. 2002. PMID: 12086562 Review.
Cited by
-
Etiology, Clinical Manifestations, Diagnosis, and Treatment of Cobalamin (Vitamin B12) Deficiency.Cureus. 2024 Jan 12;16(1):e52153. doi: 10.7759/cureus.52153. eCollection 2024 Jan. Cureus. 2024. PMID: 38344487 Free PMC article. Review.
-
Cobalamin deficiency in the elderly: aetiology and management: a study of 125 patients in a geriatric hospital.J Nutr Health Aging. 2015 Feb;19(2):234-9. doi: 10.1007/s12603-014-0525-1. J Nutr Health Aging. 2015. PMID: 25651452
-
The Impact of Vitamin B12 Supplementation on Clinical Outcomes in Patients With Diabetic Neuropathy: A Meta-Analysis of Randomized Controlled Trials.Cureus. 2022 Nov 22;14(11):e31783. doi: 10.7759/cureus.31783. eCollection 2022 Nov. Cureus. 2022. PMID: 36457818 Free PMC article. Review.
-
Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients.Drugs Aging. 2008;25(11):927-32. doi: 10.2165/0002512-200825110-00003. Drugs Aging. 2008. PMID: 18947260
-
Optimal management of pernicious anemia.J Blood Med. 2012;3:97-103. doi: 10.2147/JBM.S25620. Epub 2012 Sep 10. J Blood Med. 2012. PMID: 23028239 Free PMC article.
References
-
- Lindenbaum J., Rosenberg I.H., Wilson P.W. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr. 1994;60:2–11. - PubMed
-
- Andrés E., Goichot B., Schlienger J.L. Food cobalamin malabsorption: A usual cause of vitamin B12 deficiency. Arch Intern Med. 2000;160:2061–2062. - PubMed
-
- Loukili N.H., Andrés E. Vitamin B12 in the adult: Of metabolism and deficiencies. Ann Endocrinol (Paris) 2003;64:376–382. [in French] - PubMed
-
- Toh B.H., van Driel I.R., Gleeson P.A. Pernicious anemia. N Engl J Med. 1997;337:1441–1448. - PubMed
-
- Elia M. Oral or parenteral therapy for B12 deficiency. Lancet. 1998;352:1721–1722. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources